{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:32:37Z","timestamp":1791232357322,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>The development of monoclonal anti-amyloid antibodies, a\u00a0disease-modifying treatment for Alzheimer\u2019s disease (AD), has raised the necessity to identify the epidemiological profile of the possible target patients who would benefit from such therapy. These are patients in the early stages of AD with biomarker-confirmed brain amyloid positivity. In this study, the epidemiological profile of possible target patients in Austria and Vienna was estimated. The number of patients in the stage of amyloid-beta (A\u03b2)-positive prodromal AD in Austria and Vienna are 193,500 and 34,700 patients, respectively. The expected patient demand for the upcoming therapy in Austria and Vienna are 61,200 and 11,100 patients, respectively.<\/jats:p>\n          <jats:p>In the memory clinic of the Vienna General Hospital, the number of treatment-eligible patients for an upcoming anti-amyloid antibody was on average 52.8 patients per year, which is about 10% of the total number of patients visiting the memory clinic every year. Several challenges to provide therapy to the general population include expanding the MCI screening in primary care and increasing the capacity of the healthcare system for biomarker testing, infusion delivery, and ARIA management. The study primarily addresses the status quo of identifying patients on memory clinics through cognitive screening and biomarker testing.<\/jats:p>","DOI":"10.1007\/s00508-024-02465-8","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T09:03:40Z","timestamp":1729674220000},"page":"189-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the target patients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic"],"prefix":"10.1007","volume":"137","author":[{"given":"Seungjune","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8482","authenticated-orcid":false,"given":"Elisabeth","family":"St\u00f6gmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"1","key":"2465_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P, Bateman\u00a0RJ, Chen\u00a0C, Gee\u00a0M, et\u00a0al. Lecanemab in Early Alzheimer\u2019s Disease. N\u00a0Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"18","key":"2465_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun\u00a0MA, Lo\u00a0AC, Duggan Evans\u00a0C, Wessels\u00a0AM, Ardayfio\u00a0PA, Andersen\u00a0SW, et\u00a0al. Donanemab in early Alzheimer\u2019s disease. N\u00a0Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"2","key":"2465_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson\u00a0A, Norton\u00a0N, Fast\u00a0T, Fr\u00f6lich\u00a0L, Georges\u00a0J, Holzapfel\u00a0D, et\u00a0al. Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2023;19(2):658\u201370. https:\/\/doi.org\/10.1002\/alz.12694.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2465_CR4","first-page":"2","volume":"8","author":"JP Hlavka","year":"2019","unstructured":"Hlavka\u00a0JP, Mattke\u00a0S, Liu\u00a0JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment. RAND Health\u00a0Q. 2019;8(3):2.","journal-title":"RAND Health Q"},{"key":"2465_CR5","unstructured":"Statistik Austria. Population at the beginning of the year since 2002- (regional status of 01.01.2023). 2002. https:\/\/www.statistik.at\/. Accessed 5 Nov 2023."},{"issue":"3","key":"2465_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen\u00a0RC, Lopez\u00a0O, Armstrong\u00a0MJ, Getchius\u00a0TSD, Ganguli\u00a0M, Gloss\u00a0D, et\u00a0al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000004826.","journal-title":"Neurology"},{"issue":"19","key":"2465_CR7","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen\u00a0WJ, Ossenkoppele\u00a0R, Knol\u00a0DL, Tijms\u00a0BM, Scheltens\u00a0P, Verhey\u00a0FR, et\u00a0al. Prevalence of cerebral amyloid pathology in persons without dementia: a\u00a0meta-analysis. JAMA. 2015;313(19):1924\u201338. https:\/\/doi.org\/10.1001\/jama.2015.4668.","journal-title":"JAMA"},{"issue":"3","key":"2465_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings\u00a0J, Apostolova\u00a0L, Rabinovici\u00a0GD, Atri\u00a0A, Aisen\u00a0P, Greenberg\u00a0S, et\u00a0al. Lecanemab: appropriate use recommendations. J\u00a0Prev Alzheimers Dis. 2023;10(3):362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"2465_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1171681.10","author":"M Giorelli","year":"2023","unstructured":"Giorelli\u00a0M. Current and future perspectives of an early diagnosis of cognitive impairment. Front Neurol. 2023; https:\/\/doi.org\/10.3389\/fneur.2023.1171681.10.","journal-title":"Front Neurol"},{"key":"2465_CR10","unstructured":"Organisation for Economic Co-operation and Development. Healthcare resources [Internet]. Paris: OECD. 2024. Available from:\nhttp:\/\/stats.oecd.org\/Index.aspx?DataSetCode=HEALTH_REAC."},{"issue":"3","key":"2465_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.14283\/jpad.2020.16","volume":"7","author":"JE Galvin","year":"2020","unstructured":"Galvin\u00a0JE. Editorial: screening for mild cognitive impairment: there is the Will but is there a\u00a0way? J\u00a0Prev Alzheimers Dis. 2020;7(3):144\u20135. https:\/\/doi.org\/10.14283\/jpad.2020.16.","journal-title":"J Prev Alzheimers Dis"},{"issue":"17","key":"2465_CR12","doi-asserted-by":"publisher","first-page":"e1866","DOI":"10.1212\/WNL.0000000000201072","volume":"99","author":"A Rostamzadeh","year":"2022","unstructured":"Rostamzadeh\u00a0A, Bohr\u00a0L, Wagner\u00a0M, Baethge\u00a0C, Jessen\u00a0F. Progression of subjective cognitive decline to MCI or dementia in relation to Biomarkers for alzheimer disease: a\u00a0meta-analysis. Neurology. 2022;99(17):e1866\u2013e74. https:\/\/doi.org\/10.1212\/WNL.0000000000201072.","journal-title":"Neurology"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02465-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02465-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T15:40:53Z","timestamp":1742485253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02465-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":12,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02465-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0St\u00f6gmann received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Novo Nordisc, Eisai, Novartis, Sanofi and Lilly. Elisabeth St\u00f6gmann held leadership or a\u00a0fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia). Her institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc and Roche Diagnostics. Her institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Roche, Eisai, EU Horizon 2020 and the Austrian Alzheimer Association. S.\u00a0Lee declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}